Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

By M. Gordon. 2010

962 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/dbc2704387f9bb56cf14a5aa042167ae3a8d8f3d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Brian J. Druker
2. J. Cortes
3. Andreas Hochhaus
4. H. Kantarjian
5. M. Baccarani

In Hematology

1. Brian J. Druker
2. J. Cortes
3. J. Goldman
4. J. Apperley
5. Andreas Hochhaus
6. H. Kantarjian
7. M. Baccarani

In Rheumatology

1. Brian J. Druker
2. J. Cortes
3. Andreas Hochhaus
4. H. Kantarjian
5. M. Baccarani

Citations in the corpus

• Chronic Myeloid Leukemia (2007, positive): “Efficacy in the first-line setting was demonstrated in the phase III DASISION (Dasatinib versus Imatinib Study in Treatment-Naïve CML Patients) trial 47 .”
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013, background): “It is recommended that in practice outside of clinical trials, the firstline treatment of CP CML can be any of the 3 TKIs that have been approved for this indication and are available nearly worldwide, namely imatinib (400mg once daily), nilotinib (300mg twice daily), and dasatinib (100 mg once dail”
• Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012, neutral): “Prolonged QT interval 3 (4) 2 (2) 1 (1)”
• A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors (2011, neutral): “The understanding of the mechanistic bases for drug resistance will continue to inform the development of strategies to overcome or prevent clinical drug resistance, thereby providing a greater therapeutic benefit for cancer patients (6, 7).”
• Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial (2016, methodology): “Initial results showed that dasatinib had met its primary end point of superior efficacy compared with imatinib and had an acceptable safety profile, leading to its approval for first-line use.(1,2) In subsequent analyses,(3-6) dasatinib continued to demonstrate deep and fast responses.”